1618 - Olorofim - the first of a novel class of antifungals, the orotomides; F2G Inc

Saturday, October 22, 2022

8:20 AM – 8:30 AM US ET

Location: 145 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Speaker(s)

EH

Emma L. Harvey, MBBS

Global Head of Medical Affairs
F2G Ltd
Egham, England, United Kingdom

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Disclosure(s):

John H. Rex, MD: Advent Life Sciences: Operating Partner (), Ownership Interest (); AMR Action Fund: Advisor/Consultant (); AstraZeneca: Stocks/Bonds (); Basilea Pharmaceutica: Advisor/Consultant (); Bugworks Research, Inc.: Advisor/Consultant (); F2G, Limited: Employee (), Stocks/Bonds (); Forge Therapeutics: Advisor/Consultant (); GlaxoSmithKline: Advisor/Consultant (); Pfizer Pharmaceuticals: Honoraria (); Sumitovant: Advisor/Consultant ()